
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. demonstrated robust growth in its point-of-care (POC) and formulary offerings, with an impressive increase of over 100% during the recent buying season, underscoring strong demand for its services among medical professionals. Since the release of the recent Memorandum, Doximity's shares have experienced a modest uptick of 3.2%, indicating improved investor sentiment and market confidence in the company's growth trajectory. Additionally, the guidance for the second quarter shows achievable targets, with the potential for upside growth, reinforcing a positive outlook for the company's future performance.
Bears say
Doximity Inc. is facing a negative outlook due to downward guidance revisions from its pharmaceutical clients for fiscal years 2023 and 2024, attributed to an uncertain economic environment. Additionally, the company's stock is considered expensive when compared to its software peers, which may lead to increased volatility if financial results do not meet high investor expectations. The potential for disappointment exists, particularly if Doximity fails to deliver positive outcomes or raise guidance in response to heightened scrutiny on its financial performance.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares